Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.

Published byAmi Mosley Modified over 8 years ago

Similar presentations

Presentation on theme: "A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients."— Presentation transcript:

1 A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients (pts) with Relapsed/Refractory (R/R) Adult T-cell Leukemia-Lymphoma (ATL) Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

2 Adult T-cell Leukemia-Lymphoma (ATL) Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

3 Aggressive Subtypes of ATL have a Poor Prognosis Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

4 Treatment of ATL Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

5 Slide 5 Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

6 Slide 6 Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

7 Slide 7 Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

8 Slide 8 Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

9 Efficacy Assessments Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

10 Select Demographic Data Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

11 Results: Overall Response Rate Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

12 Summary of TEAEs (>20% in the Mogamulizumab Arm) by Treatment Arm (Safety Analysis Set) Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

13 0761-009 Study Summary Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

14 Conclusions Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

15 Investigators and Study Sites Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

16 Acknowledgements Presented By Adrienne Phillips at 2016 ASCO Annual Meeting

Download ppt "A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients."

Similar presentations

FRISC II: Fragmin and fast Revascularization during InStability in Coronary artery disease - LONG-TERM HEPARIN - Purpose To assess efficacy of long-term.

FRISC II: Fragmin and fast Revascularization during InStability in Coronary artery disease - LONG-TERM HEPARIN - Purpose To assess efficacy of long-term.
Results of the Prospective, Randomized, Multicenter FDA Investigational Device Exemption Study of the ProDisc-L Total Disc Replacement Versus Circumferential.

Results of the Prospective, Randomized, Multicenter FDA Investigational Device Exemption Study of the ProDisc-L Total Disc Replacement Versus Circumferential.
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
CM923700-1 A pooled safety & efficacy analysis examining the effect of performance status on outcomes in 9 first line treatment trials of 6,286 patients.

CM A pooled safety & efficacy analysis examining the effect of performance status on outcomes in 9 first line treatment trials of 6,286 patients.
Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.

Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.

A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.
1Coiffier B et al. Proc ASH 2010;Abstract 114.

1Coiffier B et al. Proc ASH 2010;Abstract 114.
Belinostat, a Novel Pan-Histone Deactylase Inhibitor (HDACi), in Relapsed or Refractory Peripheral T-Cell Lymphoma: Results from the BELIEF Trial1 Belinostat.

Belinostat, a Novel Pan-Histone Deactylase Inhibitor (HDACi), in Relapsed or Refractory Peripheral T-Cell Lymphoma: Results from the BELIEF Trial1 Belinostat.
Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.
Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,

Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,
Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.

Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.

Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.

This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.

Similar presentations

Ads by Google